Protea Biosciences Group Inc. announced its development of new technology that enables the direct molecular imaging of the distribution of metabolites and peptides in human clinical tissue samples. The results were presented by Dr. Erin Seeley, Principal Scientist at Protea, at the 65th Annual Meeting of the American Society for Mass Spectrometry and Allied Topics, June 4-8, held in Indianapolis, Indiana. The results showed the ability to image the distribution of both metabolites and peptides in tissue that had been preserved with formalin fixation and paraffin embedding (FFPE) protocols, which is the common method for preserving clinical samples. While preserving the tissue for archiving, FFPE preservation can limit subsequent molecular analysis.